The European Medicines Agency (EMA) and the Current Good Manufacturing Practices
(cGMP) in the United States of America, define excipient as the constituents of the …

Multiple myeloma (MM) is the second‐ranking malignancy in hematological tumors. The
pathogenesis of MM is complex with high heterogeneity, and the development of the …

Therapies against anaplastic thyroid carcinoma (ATC) have been sticking in the
predicament of multiple drug resistance (MDR). To address multiple drug resistance and …

Among the six Critical Nanoscale Design Parameters (CNDPs) proposed by Prof. Donald A.
Tomalia, this review illustrates the influence of the sixth one, which concerns the elemental …

Given the profound multiple myeloma (MM) heterogeneity in clonal proliferation of malignant
plasma cells (PCs) and anti-MM therapeutic potential of nanotherapies, it is inevitable to …

Breast cancer is one of the highest causes of mortality in women globally. Poor tumor
permeability, multidrug resistance, delayed diagnosis, and complications associated with …

In this study, a new methodology is reported for the preparation of polypropylene imine
dendrimer functionalized carbon nanotubes and a PPI/CNT nanocomposite. The PPI/CNT …

Following review summarizes the application of dendrimer-functionalized hybrid
nanomaterials. Dendrimers are nano-sized, radially symmetric molecules with well-defined …

Bortezomib (BAN) is a proteasome inhibitor approved for the treatment of multiple myeloma
and lymphoma. Despite its efficacy in various tumor models, systemic administration can …

Dendrimers are synthetic macromolecules of either symmetric or asymmetric branching
architecture that are relatively monodispersed nanomaterials and can accommodate …